Personalized Care Plans for Patients With Relapsed/Refractory Follicular Lymphoma: Dr. Loretta J. Nastoupil, MD

Follicular lymphoma is a disease that affects 2.7 per 100,000 individuals each year, with a five-year survival rate of 89.7%. It is the most common subtype of indolent non-Hodgkin's lymphoma; about 22% of newly diagnosed non-Hodgkin lymphoma cases are follicular lymphoma. The development of novel therapies offers new treatment options for patients living with follicular lymphoma. In this interview, Dr. Loretta J. Nastoupil, MD, Section Chief of New Drug Development in the Department of Lymphoma/...

Continue reading

Educational Needs in the Management of Relapsed/Refractory Follicular Lymphoma

Follicular lymphoma, an indolent, difficult-to-treat B-cell malignancy, is complicated by evolving disease subtypes. Patient outcomes can be hampered by the failure of the multidisciplinary team to establish consensus on the optimal timing, schedule, and length of follicular lymphoma treatment. In addition, the rapid pace of research makes it difficult to stay abreast of the latest and most clinically relevant therapies. This educational gap in the treatment and management of follicular lymphoma...

Continue reading

FDA Approves Axicabtagene Ciloleucel for Relapsed/Refractory Follicular Lymphoma

The FDA has granted accelerated approval to axicabtagene ciloleucel (Yescarta®, Kite Pharma, Inc.) for adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy, including the combination of an anti-CD20 monoclonal antibody and an alkylating agent. An indolent form of non-Hodgkin lymphoma (NHL) that is not generally curable, FL is considered a chronic disease. Therefore, people living with FL often require second-line therapies after their di...

Continue reading

Follicular Lymphoma: Hard to Improve on Bendamustine/Rituximab Induction

The latest data from the three-arm randomized phase 2 ECOG-ACRIN E2408 trial, which sought to improve upon frontline bendamustine/rituximab (BR) induction therapy followed by rituximab maintenance in untreated high-risk follicular lymphoma (FL), have yielded disappointing results: neither adding bortezomib to BR induction nor adding lenalidomide following BR induction improves outcomes. For the trial, 289 patients were randomized to receive either BR induction followed by two-year rituximab main...

Continue reading

Tazemetostat for Follicular Lymphoma Granted Accelerated Approval

Tazemetostat (TAZVERIK™, Epizyme, Inc.) has been approved for adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) who have tumors that are positive for an EZH2 mutation, have received at least 2 previous systemic therapies, and have no satisfactory alternative treatment options. In addition, the FDA approved the cobas® EZH2 Mutation Test (Roche Molecular Systems, Inc.) as a companion diagnostic for tazemetostat. An EZH2 inhibitor, tazemetostat has previously been approved f...

Continue reading


Get the latest updates delivered to your inbox!

Follow Us

Copyright © 2022 Oncology Data Advisor. All rights reserved.